What’s happening at BridgeBio Pharma, Inc. (NasdaqGS:BBIO)? What made the stock one of the top performing stock today? The company is indeed among the top gainers of the stock market, skyrocketing 10.07% (or 3.52 points) to $38.46 from its previous close of $34.94. So is it the right moment to buy?
The shares had a decreased trading volume of 275,151 contracts this session compared to the average daily volume of last 10 days of 293,087 contracts and they had a decreased trading volume compared to the average daily volume of last 3 months of 317,387 contracts.
The indicator of a company’s profitability, the earnings per share ratio is -4.73. This value shows how much money a company makes for each share of its stock. A higher EPS indicates more value because investors will pay more for a company with higher profits. This is negative and tells you exactly how much money the company lost per share of its 123.6M outstanding stock.
The closing market price for this trading session was 118.40% over 52 weeks minimum price of $17.61 and 2.98% under 52 weeks maximum price of $39.64. Also the price is 43.12% greater than 200 day average of $26.87 and 27.54% greater than 50 day average of $30.15.
Latest news that might have contributed to the great perfomance of BBIO today are:
- BridgeBio Pharma’s Origin Biosciences Enters Partnership With Medison to Commercialize BBP-870 in Israel for MoCD Type A, published on Wed, 18 Dec 2019 12:30:10 +0000
- BridgeBio Pharma, Inc. Appoints Industry Leader Jennifer Cook as New Board Member, published on Mon, 16 Dec 2019 12:30:10 +0000
- BridgeBio Pharma, Inc. (BBIO): Are Hedge Funds Right About This Stock?, published on Fri, 13 Dec 2019 17:37:38 +0000